How to appeal a Highmark pediatric epilepsy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for pediatric epilepsy

Cited policy: BCBS Epilepsy Surgery (Resective / Disconnective / LITT) for Drug-Resistant Pediatric Epilepsy

Drug-resistant epilepsy per ILAE Kwan 2010 (failed >=2 appropriate AEDs at adequate doses). Phase 1 evaluation at level-4 NAEC-accredited epilepsy center: video-EEG with seizures captured, 3T MRI epilepsy protocol, neuropsych, and as indicated PET / SPECT / MEG / fMRI / WADA. Multidisciplinary epilepsy surgery conference recommendation. Procedures covered: focal resection / lesionectomy / temporal lobectomy / hemispherectomy / corpus callosotomy / LITT (laser ablation). Pediatric coverage with developmental urgency.

How Highmark denies pediatric epilepsy — and how to counter it

Where Highmark pushes back: 1) Surgery too aggressive for a child; 2) Try more medications first; 3) LITT experimental; 4) Hemispherectomy too radical without exhausting other options.

Counter-arguments that hold up: Pediatric Epilepsy Surgery RCT — Dwivedi NEJM 2017 — 77% seizure-free at 12 mo surgery vs 7% medical. AAN/AES 2018 Kanner — refer to comprehensive epilepsy center after 2 AED failures. Engel Class I 60-80% in lesional pediatric candidates. Earlier surgery preserves neurodevelopment + reduces SUDEP risk (Harden AAN/AES 2017 SUDEP guideline). LITT is FDA-cleared (Visualase / NeuroBlate) and standard of care for selected mesial temporal + hypothalamic hamartoma + insular targets — NOT experimental. Hemispherectomy is established standard for catastrophic unihemispheric epilepsy (Rasmussen, hemimegalencephaly, large infarct, Sturge-Weber).

What Highmark typically denies for pediatric epilepsy

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric epilepsy, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the pediatric epilepsy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Epidiolex
• Fintepla
• Diacomit
• Clobazam (Onfi/Sympazan)
• Banzel
• Ztalmy (CDKL5)

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.